Cerus develops and commercializes pathogen inactivation technology for blood transfusion safety, led by the INTERCEPT Blood System for platelets and plasma. The platform is designed to inactivate a broad range of viruses, bacteria, and other pathogens in donated blood components before transfusion. Hospitals, blood centers, and national blood services are the primary customers, particularly where regulators or health systems require or encourage pathogen-reduced components. The company’s niche is blood safety technology rather than broad diagnostics or pharmaceutical manufacturing.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 43.2 | — | -7.7 | — |
| Q2 2025 | 52.5 | — | -5.7 | — |
| Q3 2025 | 52.7 | — | -0 | — |
| Q4 2025 | 57.8 | — | -2.2 | — |
| Q1 2026 | 53.7 | 24.1% | -1.6 | — |
| Q2 2026 | 57.4 | 9.5% | -2.9 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Malibu Boats, Inc. (MBUU), Infinite Eagle Acquisition Corp. (IEAG), Eupraxia Pharmaceuticals Inc. (EPRX), Idea Acquisition Corp. (IACO), D. Boral Acquisition I Corp. (DBCA), RBB Bancorp (RBB)